Company intelligence / Profile preview
Kureha
Chuo-ku, Tokyo, Japankureha.co.jp ↗
- Ownership
- Private
- Employees
- ~4374
- Development stage
- Commercial
01
Overview
Kureha has developed and commercialized several pharmaceutical products, including "Krestin" for cancer immunotherapy and "Kremezin" for chronic kidney disease. Some pipeline programs have been discontinued, while others are in various stages of development or regulatory review.
- Therapeutic areas
- OncologyRheumatologyImmunologyNephrology
- Modalities
- Small moleculeBiologicMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Claros Technologies (PFAS remediation technology partnership)Celanese (Fortron Industries joint venture for polyphenylene sulfide production)
Beyond the preview
Go deeper on Kureha.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kureha.